These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 17230464)

  • 1. Punding prevalence in Parkinson's disease.
    Miyasaki JM; Al Hassan K; Lang AE; Voon V
    Mov Disord; 2007 Jun; 22(8):1179-81. PubMed ID: 17230464
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Punding in Parkinson's disease: its relation to the dopamine dysregulation syndrome.
    Evans AH; Katzenschlager R; Paviour D; O'Sullivan JD; Appel S; Lawrence AD; Lees AJ
    Mov Disord; 2004 Apr; 19(4):397-405. PubMed ID: 15077237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
    Talati R; Baker WL; Patel AA; Reinhart K; Coleman CI
    Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Levodopa-dyskinesia incidence by age of Parkinson's disease onset.
    Kumar N; Van Gerpen JA; Bower JH; Ahlskog JE
    Mov Disord; 2005 Mar; 20(3):342-4. PubMed ID: 15580606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of Parkinson's disease in Spain.
    Grandas F; Kulisevsky J
    Mov Disord; 2003 Jan; 18(1):87-9. PubMed ID: 12518304
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The management approaches to dyskinesia vary from country to country.
    Woitalla D; Mueller T; Russ H; Hock K; Haeger DA
    Neuroepidemiology; 2007; 29(3-4):163-9. PubMed ID: 18043000
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Levodopa: management of Parkinson's disease.
    Mov Disord; 2002; 17 Suppl 4():S23-37. PubMed ID: 12211137
    [No Abstract]   [Full Text] [Related]  

  • 8. Prospective prevalence of pathologic gambling and medication association in Parkinson disease.
    Voon V; Hassan K; Zurowski M; Duff-Canning S; de Souza M; Fox S; Lang AE; Miyasaki J
    Neurology; 2006 Jun; 66(11):1750-2. PubMed ID: 16769956
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Estimation of the prevalence of Parkinson's disease in Asturia, Spain. A pharmacoepidemiological study of the consumption of antiparkinson drugs].
    Martínez-Suárez MM; Blázquez-Menes B
    Rev Neurol; 2000 Dec 1-15; 31(11):1001-6. PubMed ID: 11190861
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa.
    Hauser RA; Rascol O; Korczyn AD; Jon Stoessl A; Watts RL; Poewe W; De Deyn PP; Lang AE
    Mov Disord; 2007 Dec; 22(16):2409-17. PubMed ID: 17894339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Early treatment of Parkinson's disease with levodopa].
    Odekerken VJ; Post B; Verschuur CV; de Bie RM
    Ned Tijdschr Geneeskd; 2009; 153():A286. PubMed ID: 19785822
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Slowing of oscillatory brain activity is a stable characteristic of Parkinson's disease without dementia.
    Stoffers D; Bosboom JL; Deijen JB; Wolters EC; Berendse HW; Stam CJ
    Brain; 2007 Jul; 130(Pt 7):1847-60. PubMed ID: 17412733
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ongoing challenges to finding people with Parkinson's disease for epidemiological studies: a comparison of population-level case ascertainment methods.
    Harris MA; Koehoorn M; Teschke K
    Parkinsonism Relat Disord; 2011 Jul; 17(6):464-9. PubMed ID: 21531606
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment with levodopa and risk for malignant melanoma.
    Olsen JH; Tangerud K; Wermuth L; Frederiksen K; Friis S
    Mov Disord; 2007 Jul; 22(9):1252-7. PubMed ID: 17534943
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Compulsive singing: another aspect of punding in Parkinson's disease.
    Bonvin C; Horvath J; Christe B; Landis T; Burkhard PR
    Ann Neurol; 2007 Nov; 62(5):525-8. PubMed ID: 17696122
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of non-motor dysfunction among Parkinson's disease patients from a tertiary referral center in Mexico City.
    Rodríguez-Violante M; Cervantes-Arriaga A; Villar-Velarde A; Corona T
    Clin Neurol Neurosurg; 2010 Dec; 112(10):883-5. PubMed ID: 20800345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between visual hallucinations and REM sleep behavior disorder in patients with Parkinson's disease.
    Meral H; Aydemir T; Ozer F; Ozturk O; Ozben S; Erol C; Cetin S; Hanoglu L; Ozkayran T; Yilsen M
    Clin Neurol Neurosurg; 2007 Dec; 109(10):862-7. PubMed ID: 17913346
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Levodopa and cognitive disorders in Parkinson's disease].
    Leiva-Santana C; Alvarez-Saúco M
    Rev Neurol; 2006 Jul 16-31; 43(2):95-100. PubMed ID: 16838257
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypothyroidism and Parkinson's disease.
    Teive HA; Munhoz RP
    Mov Disord; 2004 Sep; 19(9):1116-7; discussion 1117. PubMed ID: 15372612
    [No Abstract]   [Full Text] [Related]  

  • 20. [The prevalence of idiopathic Parkinson's disease].
    Giroud-Benítez JL
    Rev Neurol; 2001 Oct 1-15; 33(7):700. PubMed ID: 11784961
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.